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Abstract 
Purpose: Human tumors are often resistant to type 5 adenoviruses (Ad5)-mediated gene transfer. We 
examined cytotoxicity of replication-competent Ad5 of which the receptor-binding site was replaced 
with that of serotype 35 (AdF35) and investigated possible combinatory effects of the AdF35 and 
Ad5 expressing the wild-type p53 gene (Ad5/p53). 
Experimental Design: We tested AdF35 infectivity to 9 kinds of human esophageal carcinoma with 
flow cytometry and examined cytotoxicity of replication-competent AdF35 powered by the midkine 
or the survivin transcriptional regulatory region. Western blot analyses and cell cycle analyses were 
used to investigate cell death induced by the AdF35. Possible combinatory effects were also tested 
with a calorimetric analysis and in an animal model. 
Results: Replication-competent AdF35 in general achieved greater cytotoxic effects to esophageal 
carcinoma cells than the corresponding replication-competent Ad5. Cytotoxicity of the AdF35 was 
accompanied by cleavage of capases and increased sub-G1 fractions, but was not linked with 
autophagy pathways. Transduction with Ad5/p53 in combination with replication-competent AdF35 
further enhanced the AdF35-mediated cytotoxicity in a synergistic manner. We also demonstrated the 
combinatory effects in an animal model. Transduction with Ad5/53 was rather inhibitory to 
production of replication-competent AdF35 progenies, but the AdF35 infection augmented p53 
expression levels and the phosphorylation. 
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Conclusion: Combination of replication-competent AdF35 and Ad5/p53 achieved synergistic 
cytotoxicity due to enhanced p53-mediated apoptotic pathways. 
3 
 
Introduction 
 Esophageal squamous cell carcinoma, which frequently developed in aged persons, remains 
intractable despite a recent progress in multi-modal treatments. Adenoviruses (Ad)-mediated gene 
transfer is a possible strategy to improve the prognosis by transducing the tumor cells with an 
exogenous therapeutic gene. Type 5 Ad, which utilize the coxsackie adenovirus receptor (CAR) 
molecules as one of the major cellular receptors, are most commonly used for gene transfer but Ad5-
mediated transduction is partly subjected to an expression level of CAR on the target cells (1). 
Expression of CAR, ubiquitously detected in the epithelium, is often down-regulated in various 
human tumors including esophageal carcinoma cells, which results in inefficient Ad5-mediated 
transduction (2, 3). Type 35 Ad (Ad35) use CD46 molecules as a main cellular receptor and 
ubiquitously expressed levels of CD46 are well maintained even in human tumors in contrast to CAR 
(4, 5). Previous studies showed that chimeric Ad5 vectors of which the fiber-knob portion was 
replaced by that of Ad35 (AdF35) infected target cells with the same efficacy as Ad35 (1, 6). The 
AdF35 can thereby be an alternative vector to transduce low CAR-expressing cells, which are 
resistant to Ad5 infection. The differential receptor usage has another advantage in simultaneously 
transferring multiple genes into the same target cells. Ad5 infection down-regulated CAR expression 
levels on target cells and inhibited subsequent transduction of the cells with Ad5. AdF35-mediated 
transduction was however not impaired by precedent Ad5 infection since the down-regulated 
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receptor expression was exclusive each other (7). 
 Conditionally replication-competent Ad, designed to propagate specifically in tumors followed 
by spreading the viral progenies to neighboring tumor cells, can overcome low transduction efficacy 
and limited anti-tumor effects, both of which are observed with replication-incompetent Ad (8). We 
previously demonstrated that a transcriptional regulatory region of the midkine (MK) gene, which 
was expressed in a number of human tumors but scarcely in normal tissues (9), and that of the 
survivin (Sur) gene, the product of which played a role in anti-apoptosis and was involved in mitotic 
regulation (10), effectively activated an exogenous gene preferentially in tumors (11-13). Moreover, 
we demonstrated that replication-competent Ad5 of which the E1 genes were activated by the MK 
regulatory region produced anti-tumor effects on hepatocellular carcinoma (14).  
 Ad5 expressing the wild-type p53 gene (Ad5/p53) have been clinically in use for cancer 
treatments and produced combinatory anti-tumor effects with chemotherapeutic agents (15, 16). We 
also demonstrated that Ad5/p53 produced cytotoxic effects on human esophageal carcinoma and that 
the cytotoxicity was linked with CAR expression levels (17). These results raise a possibility that 
forced p53 expression in combination with replication-competent Ad achieved further anti-tumor 
actions, which could be a novel therapeutic strategy for esophageal carcinoma. In this study, we 
examined cytotoxicity of replication-competent AdF35 powered by regulatory region of MK or Sur 
on a panel of human esophageal carcinoma cells and examined a possible combinatory effects of 
5 
 
Ad5/p53 and the AdF35. 
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Materials and methods 
Cells and mice 
Human esophageal squamous cell carcinoma lines, TE-1, TE-2, TE-10, TE-11, YES-2, YES-4, YES-
5, YES-6 and T.Tn cells, were cultured with RPMI 1640 medium supplemented with 10% fetal calf 
serum. The p53 genetic status of respective tumors is shown in Table 1. Human embryonic kidney 
(HEK) 293 cells were cultured with DMEM medium supplemented with 10% fetal calf serum. 
BALB/c nu/nu mice (5-6 week-old females) were purchased from Japan SLC (Hamamatsu, Japan). 
 
Ad preparation 
Replication-incompetent Ad5 DNA bearing the wild-type p53, the green fluorescent protein 
(Ad5/GFP) and the -galactosidase gene (Ad5/LacZ) was constructed by ligation of the transgene-
harboring pShuttle 2 (Takara, Tokyo, Japan) and Adeno-X vector (Takara). Ad35 DNA bearing the 
above transgenes (AdF35/GFP, AdF35/LacZ) was produced with Adeno-X vector substituted with 
the Ad35 fiber-knob region. The fiber-knob modified Adeno-X DNA was created by replacing a 
fragment containing the Ad35 fiber-knob region (Avior therapeutics, Seattle, WA) (AY271307 at 
30827-33609) with that of Ad5-derived region. The replication-incompetent Ad used the 
cytomegalovirus promoter to activate the transgene. Replication-competent Ad DNA of which the E1 
gene was powered by a transcriptional regulatory region of the midkine or the survivin gene 
(Ad5/MK, AdF35/MK, Ad5/Sur, AdF35/Sur) were prepared with the regulatory sequences-harboring 
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pShuttle 2 and Adeno-X vector or the fiber-knob replaced Adeno-X vector. The Ad DNA was 
transfected into HEK293 cells and the Ad were purified with Adeno-X purification kit (Takara). 
 
Infectivity of Ad 
Cells were infected with Ad5/GFP or AdF35/GFP at 30 multiplicity of infection (MOI) for 30 min 
and were washed to remove Ad. They were cultured for 2 days and were analyzed for the 
fluorescence with FACSCalibur and CellQuest software (BD Biosciences, San Jose, CA, USA). Cell 
populations that showed fluorescence greater than the brightest 5% of uninfected cells were judged 
as positively stained. 
 
Cell cycle analysis 
Cells were fixed in 100% ethanol, treated with RNase (50 μg/ml) and stained with propidium iodide 
(50 μg/ml). Cell cycle distributions were analyzed with FACSCalibur and CellQuest software. 
 
In vitro cytotoxicity assay and cell proliferation 
Cells were seeded in 96-well plates (5x10
3
/well), infected with Ad at different amount of virus 
particles (vp) and were cultured for 5-6 days. Cell viability was determined with a cell-counting 
WST kit (Wako, Osaka, Japan) and the relative viability was calculated based on the absorbance 
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without any treatments. Combinatory effects between AdF35/MK or AdF35/Sur and Ad5/p53 were 
examined with CalcuSyn software (Biosoft, Cambridge, UK). Combination index (CI) values were 
calculated based on the cell viability test with various vp of AdF35/MK or AdF35/Sur and Ad5/p53 
(1.25104 vp/cell) and were shown with fractions affected (Fa) by respective Ad doses. A CI value 
equal to 1 denotes an additive interaction, above 1 antagonism and below 1 synergism. Live cell 
numbers were calculated with a trypan blue dye exclusion test. 
 
Western blot analysis 
Cell lysate was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis. The protein 
was transferred to a nylon filter and was hybridized with antibodies (Ab) against Ad hexon, (Abcam, 
Cambrige, UK), Ad E1A (Santa Cruz Biotech, Santa Cruz, CA, USA), poly (ADP-ribose) 
polymerase (PARP), caspase-3, cleaved caspase-3, caspase-8 (also detect cleaved caspase-8), 
caspase-9 (detect cleaved caspase-9), Fas-Associated protein with death domain (FADD), TRAIL 
receptors (DR5), Bid, truncated Bid (t-Bid) (Cell Signaling, Danvers, MA, USA), p53 (Lab Vision, 
Fremont, CA, USA), phosphorylated p53 at Ser 15 or at Ser 46 (Cell Signaling), Atg5, LC3A/B, 
Beclin-1 (Cell Signaling), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Abcam) or -
tubulin (Thermo Fisher Scientific, Fremont, CA, USA). The membranes were developed with the 
ECL system (GE Healthcare, Buckinghamshire, UK). 
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Animal experiments 
YES-2 cells (1×106) were subcutaneously injected into BALB/c nu/nu mice and the mice received 
an intratumoral injection of Ad (2.5×108 pfu/mouse) 4 times. In combinatory experiments, mice 
received intratumoral injection of AdF35 (1.875×108 pfu/mouse) and/or Ad5 (1.875×108 
pfu/mouse) when the tumors reached to about 65 mm
3
 in volume. Tumor volumes were calculated 
according to the formula (1/2 x length x width
2
). The animal experiments were approved by the 
animal experiment and welfare committee at Chiba University and were performed according to the 
guideline on animal experiments. 
 
Viral production assay 
YES-2 cell lysate after Ad infection was examined for the cytotoxicity with HEK293 cells and the 
virus titers were calculated with the median tissue culture infectious dose (TICD50) method. 
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Results 
Greater transduction with AdF35 
We compared infectivity of Ad5 and AdF35 vectors to 9 kinds of human esophageal carcinoma cells 
using GFP-expressing Ad with flow cytometry (Table 1). The differential fluorescence intensity of 
Ad5/GFP and AdF35/GFP in the same cells was influenced by the Ad infectivity since the same 
cytomegalovirus promoter was used to activate the GFP gene. The esophageal carcinoma cells were 
relatively resistant to Ad5-mediated transduction compared with HEK293 cells. All the esophageal 
cells however showed greater infectivity with AdF35/GFP than with Ad5/GFP in contrast to HEK293 
cells which showed similar transduction with Ad5/GFP and AdF35/GFP. 
 
Compared cytotoxicity between replication-competent AdF35 and Ad5 
We examined the cytotoxic activity of replication-competent AdF35 and Ad5 on esophageal 
carcinoma cells, and compared the activity between Ad5/MK and AdF35/MK (Fig. 1A), and Ad5/Sur 
and AdF35/Sur in the same cells (Fig. 1B). Susceptibility to replication-competent Ad was different 
among the cells tested, but AdF35 produced in some of cells greater cytotoxicity than corresponding 
Ad5 irrespective of the regulatory region. AdF35/MK achieved cytotoxic effects relatively greater 
than Ad5/MK in TE-1, YES-2, YES-5 and T.Tn cells, whereas the cytotoxicity between the 2 kinds 
of Ad was similar in other cells and YES-6 cells were resistant to the Ad-mediated cytotoxicity. 
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AdF35/Sur also produced greater cytotoxicity than Ad5/Sur in TE-1, TE-2, TE-10, YES-2, and T.Tn 
cells, whereas both types of Ad showed similar cytotoxicity in other cells. AdF35/LacZ or Ad5/LacZ 
did not influence the viability or was minimally inhibitory at the high Ad doses. These data 
collectively suggest that AdF35 held an advantage over Ad5 in the cytotoxicity to some of the cells 
such as TE-1, YES-2 and T.Tn cells. 
 
Cell cycle distribution induced by Ad infections 
We examined cell cycle changes induced by AdF35 infections in T.Tn and YES-2 cells (Fig. 2A) 
(Table 2). AdF35/MK- and AdF35/Sur-infected cells initially increased a fraction with more than 4N 
population (hyperploidy) and subsequently sub-G1 populations in a time-dependent manner. 
AdF35/LacZ-infected cells did not show significant changes in cell cycle compared with uninfected 
cells. Both T.Tn and YES-2 cells showed a small percentage of hyperploidy fractions in uninfected 
states and AdF35/LacZ infection did not influence the percentages. 
 
Replication-competent Ad activated apoptotic pathways 
We further examined molecular events caused by replication-competent Ad-mediated cytotoxic 
actions with western blot analyses (Fig. 2B-D). Transduction of T.Tn and YES-2 cells with 
AdF35/MK or AdF35/Sur but not AdF35/LacZ induced both E1A, early viral protein, and hexon, late 
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viral protein (Fig. 2B). We then examined possible activation of apoptosis pathways (Fig. 2C). 
Transduction with AdF35/MK or AdF35/Sur but not AdF35/LacZ induced cleavage of PRAP and 
caspase-3 in both cell lines, demonstrating replication-competent Ad achieved apoptotic cell death. 
Ad-infected T.Tn cells showed cleavage of both caspase-8, involved in the extrinsic cell death, and 
caspase-9, involved in the intrinsic mitochondria-mediated cell death, whereas Ad-infected YES-2 
cells showed cleavage of caspase-9 but not casepase-8. Truncated Bid was minimally detected only 
in YES-2 cells. We also examined expression levels of the molecules in upstream pathways of the 
extrinsic apoptosis and found that expression levels of FADD and TRAIL receptors, DR5, remained 
unchanged in YES-2 cells, but DR5 slightly increased in T.Tn cells. These data thereby demonstrated 
that both the intrinsic and the extrinsic pathways were activated in T.Tn cells, whereas the intrinsic 
apoptosis was preferentially induced in YES-2 cells. We further investigated expression levels of 
Atg5, Beclin-1, and LC3A/B-I and II, which were linked with the autophagy pathways (Fig. 2D). 
These levels were scarcely influenced by AdF35/MK or AdF35/Sur except slight increase of 
LC3A/BII in YES-2 cells. These data suggested that AdF35/MK and AdF35/Sur induced caspase-
mediated apoptotic pathways with a cell type-dependent involvement of the extrinsic pathway, and 
that autophagy pathways minimally contributed to the Ad-mediated cytotoxicity. 
 
Replication-competent Ad produced anti-tumor effects in vivo 
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We investigated the anti-tumor effects of replication-competent Ad in an animal model (Fig. 3). 
Nude mice bearing subcutaneous YES-2 tumors were treated with an intratumoral injection of 
AdF35/MK, AdF35/Sur or AdF35/LacZ as a control. Administration of AdF35/MK and AdF35/Sur 
but not AdF35/LacZ retarded the subsequent tumor growth, demonstrating the Ad-mediated ant-
tumor effects in vivo. 
 
Combinatory effects of replication-competent AdF35 and Ad5/p53 
We examined possible combinatory effects between AdF35/MK or AdF35/Sur and Ad5/p53 (Fig. 4). 
Both YES-2 and T.Tn cells had mutated p53 genes and were susceptible to Ad5/p53-mediated 
cytotoxicity (17). These cells were infected with different amounts of replication-competent AdF35 
or Ad5/p53, or in combination with AdF35 and Ad5/p53. The combinatory treatment with 
AdF35/MK and Ad5/p53 produced greater cytotoxicity than respective Ad alone in both T.Tn and 
YES-2 cells (Fig. 4A). The CI values at Fa points between 0.3 and 0.8 in T.Tn cells or 0.2 and 0.8 in 
YES-2 cells indicated the combination produced synergistic effects. Transduction with Ad5/p53 also 
enhanced AdF35/Sur-induced anti-tumor effects in both cells and the CI values at the same Fa ranges 
showed the synergism between AdF35/Sur and Ad5/p53 in the cytotoxicity (Fig. 4B). 
 
Growth inhibition by combination of replication-competent AdF35 and Ad5/p53 
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We also investigated a combinatory effect of replication-competent Ad and Ad5/p53 on cell 
proliferation (Table 3). YES-2 cells were infected with replication-competent AdF35 with Ad5/p53 
or Ad5/LacZ, and then live cell numbers were counted. A combinatory use of AdF35/MK or 
Ad5F35/Sur and Ad5/p53 inhibited cell proliferation greater than AdF35/MK, AdF35/Sur or Ad5/p53 
alone. We then examined the cell cycle changes after the combination treatment with AdF35/MK and 
Ad5/p53 (Fig. 5A) (Table 4). Infection with Ad5/p53 slightly increased G0/G1 and sub-G1 fractions 
in YES-2 cells, and AdF35/MK infection resulted in induction of hyperploidy populations. In 
contrast, transduction with both AdF35/MK and Ad5/p53 rather decreased hyperploidy fractions and 
greatly increased sub-G1 populations, suggesting that the combination augmented apoptotic cell 
death. 
 
In vivo anti-tumor effects by Ad5F35/MK and Ad5/p53  
We investigated the anti-tumor effects produced by Ad5F35/MK and Ad5/p53 in an animal model 
(Fig. 5B). Nude mice injected with YES-2 cells were treated with intratumoral administration of 
Ad5F35/MK and/or Ad5/p53. Tumor growth of mice treated with AdF35/MK plus Ad5/p53 was 
retarded compared with that of mice injected with either AdF35/MK or Ad5/p53 alone. In contrast, 
Ad5/LacZ treatments did not produce any combinatory effects with AdF35/MK although 
AdF35/LacZ alone slightly inhibited the tumor growth compared with Ad5/LacZ injections. 
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Mechanisms of combinatory effects by replication-competent AdF35 and Ad5/p53 
We examined whether the enhanced anti-tumor effects of replication-competent AdF35 by Ad5/p53 
infection were associated with increased production of the viral progenies. YES-2 cells were infected 
with AdF35/MK or AF35/Sur and Ad5/p53, and the cell lysate was tested for the viral amounts 
produced (Fig. 5C). Ad5/p53 infection suppressed propagation of AdF35/MK at day 3 and 4, and that 
of AdF35/Sur at day 4. The enhanced apoptosis by co-infected Ad5/p53 was not thereby due to 
increased production of infectious Ad progenies, but could be linked with augmented p53 functions. 
We then examined p53 activation processes with western blot analyses (Fig. 5D). Transduction of 
YES-2 cells with Ad5/p53 increased p53 expression levels and the phosphorylation at Ser 15 
residues, whereas AdF35/MK infection did not augment the p53 and the phosphorylation. In contrast, 
a combinatory use of AdF35/MK and Ad5/p53 up-regulated p53 phosphorylation both at Ser 15 and 
Ser 46 residues. Ad5/LacZ did not modulate endogenous p53 expression levels or induce the 
phosphorylation. These data showed that AdF35/MK activated the signal pathways that led to p53 
phosphorylation. 
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 Discussion 
 In this study, we demonstrated that replication-competent AdF35 regulated by an exogenous 
transcriptional regulatory region induced apoptotic cell death of esophageal carcinoma and that 
combination of the AdF35 and Ad5/p53 produced synergistic cytotoxicity through enhanced p53 
phosphorylation. Direct injection of the mixed Ad vectors into esophageal carcinoma is technically 
feasible and the up-regulated p53 pathways by the combinatory Ad usage can also contribute to 
enhanced sensitivity to chemotherapeutic agents and radiotherapy. 
 Fiber-modified AdF35 targeting CD46 molecules have several advantages. The basic Ad 
structure is derived from type 5 Ad of which the biological and genetic properties are well known 
and the infectivity to human tumors is not down-regulated as found in Ad5 vectors (18). Ubiquitous 
distribution of CD46 molecules among normal tissues however needs tumor-specific replications for 
safety in the case of replication-competent Ad. The transcriptional regulatory regions of MK and Sur 
used in AdF35 can distinctively activate therapeutic gene with high tumor selectivity and suitable for 
drive the E1A gene (11-13). Infection of Ad down-regulated the receptor expression on target cells 
and inhibited subsequent transduction by the same Ad but not by irrelevant Ad type with different 
receptor usage. Ad5 and AdF35 did not suppress reciprocal infection and consequently both vector 
systems are compatible in dual gene transfer (7). We took an advantage of the mutually uninhibited 
infection with AdF35 and Ad5 vectors to examine possible combinatory cytotoxicity. 
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 Combinatory effects of replication-competent Ad and forced expression of p53 can be examined 
either with a dual Ad transduction method or with a single vector system in which the p53 gene was 
integrated into replication-competent Ad and was co-amplified together with viral replication. 
Previous studies dealing with the dual Ad mixtures demonstrated that combinatory cytotoxicity was 
achieved with replication-incompetent Ad5/p53 and either wild-type Ad5 (19) or replication-
competent Ad5 of which the replications were activated by telomerase reverse transcriptase (TERT) 
promoter (20). These studies used an Ad5 system in any of the vectors, and did not consider possible 
decreased infectivity to target cells or influence of the viral ratios between replication-competent Ad 
and Ad5/p53 on the cytotoxicity. Another strategy also achieved the combinatory effects with 
replication-competent Ad5 bearing the wild-type p53 gene, of which the E1 region genes were driven 
by Sur (21) or TERT promoter (OBP-702) (22, 23). These p53 co-amplification studies showed that 
production of viral progenies was not disturbed by expressed p53 and suggested that down-regulated 
p21 and Mdm-2, both of which were favorable to apoptosis induction and p53 up-regulation, 
respectively, were associated with Ad-mediated both apoptosis and autophagy (22, 23). In contrast, 
the present study demonstrated that productions of AdF35/MK and AdF35/Sur progenies were 
inhibited by co-transduced p53, and phosphorylated p53 at Ser 15 and 46, which were linked with 
increased p53 stability by dissociating p53 from Mdm-2 and apoptosis induction, respectively, was 
associated with the combinatory effects. These discrepant results could be resulted from amounts of 
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p53 produced in respective studies and attributable to genetic difference of cells infected. 
 Cell death mechanisms mediated by replication-competent Ad is complex. The present study 
showed that the cytotoxicity was not attributable to autophagy but to caspase-associated apoptosis 
although activation of the intrinsic and extrinsic pathways was dependent on cells types tested. 
Interestingly, Yamazaki et al. showed that OBP-702, p53-expressing and TERT promoter activated 
replication-competent Ad induced apoptosis in lung carcinoma cells and T.Tn cells (22), but Hasei et 
al. demonstrated with the same OBP-702 killed osteosarcoma cells through autophagy (23). 
Replication of wild-type Ad was previously shown to induce cell death based on balance between 
pro-apoptotic and anti-apoptotic actions, which was partly linked with expressed E1B-19kDa 
molecules (24). Recent studies also demonstrated that Ad induced autophagy-mediated cell death 
with an elevated caspase activity in the extrinsic pathways (25). These reports together with the 
present data suggest that Ad replication-mediated cell death is subjected to multiple factors including 
genetic differences of the infected cells, which are resulted in varied susceptibility between apoptosis 
and autophagy.  
 We found that phosphorylation of Ad-induced p53 at Ser 15 was enhanced and that at Ser 46 was 
induced by co-infected replication-competent AdF35. A possible upstream pathway involved in the 
p53 phosphorylation in both residues remains uncharacterized. Ad proteins produced during the 
replication, which may be associated with DNA damages, induced the phosphorylation of 
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exogenously produced p53 but not of endogenous p53. YES-2 cells have mutated p53 at Tyr 236 not 
at Ser 15 or 46, and the endogenous p53 at the residues thereby can be phosphorylated. Interactions 
between Ad protein and endogenous p53 are complex and several Ad proteins in fact regulated p53 
expression by influencing the stability. Ad E4-ORF3 protein for example was recently shown to 
prevent the binding of p53 to the target sequences and to silence p53-mediated transactivation in an 
epigenetic manner (26). The p53 pathways after Ad infection are thereby regulated by multiple 
factors and furthermore are controlled by anti-viral proteins such as infection-induced interferons as 
well (27).  
 A biomarker to predict the efficacy of Ad-mediated cytotoxicity to target tumors is preferable in 
the case of its clinical application. A mechanism of Ad-induced cell death remains uncharacterized at 
present since a number of factors were involved. In contract, Ad infectivity seems to be one of the 
factors that influence the cytotoxicity. We previously analyzed a possible correlation between Ad 
receptor expression levels in target cells and the infectivity (18). AdF35 used primarily CD46 
molecules as the major receptor but the infectivity was not dependent on the expression levels 
probably because AdF35 use other molecules as an auxiliary receptor and a possible threshold level 
of receptor molecules could be different among the target cells (18). Nevertheless, AdF35 in general 
showed greater infectivity to low CAR-expressing cells such as TE-1, YES-2 and T.Tn cells (17), 
which is advantageous for transduction of human tumors. Infectivity of AdF35 to tumors was 
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however not different from that of Ad5 when the target tumors expressed a certain level of CAR 
molecules, suggesting that advantage of AF35 as a vector is relatively limited. We also examined the 
relationship between the p53 status and AdF35-mediated cytotoxicity, and found that the status was 
irrelevant to sensitivity to the cell death. 
 We noticed that replication-competent AdF35 induced hyperploid populations which preceded 
increase of sub-G1 fractions. Cherubini et al showed that replication-competent Ad with deletion of 
the E1B region encoding E1B55kDa molecules induced hyperpoidy populations in the infected 
normal cells, and suggested a possible linkage with increase expression of Mda2 (28), which was a 
major component of M-phase checkpoint (29). The study also indicated that wild-type Ad did not 
induce the hyperploidy and subsequently ruled out a possibility that the hyperploidy was caused by 
amplified viral DNA contents (28). Our previous study also found the E1B55kDa-defective Ad 
induced similar hyperploidy in mesothelioma cells without any changes at host chromosome levels 
(30). Our preliminary data also showed that the wild-type Ad minimally induced hyperploidy but 
rapidly increased sub-G1 fractions in esophageal carcinoma (data not shown). These data suggest 
that Ad replication processes is not directly associated with hyperploidy, but differential cell death 
mechanisms which are influenced by a number of genetic varieties of infected cells may contribute 
to the aberrant cell cycle population. Further investigations on genesis of the hyperploidy can require 
genetically modified cells to standardize the genetic backgrounds. 
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 Esophageal carcinoma can be an ideal target for gene therapy. Several studies demonstrated the 
clinical feasibility (31, 32) and our previous clinical study with Ad5/p53 showed that direct 
administration of Ad induce none of the major adverse effects (33). In conclusion, we demonstrated 
that combination of replication-incompetent Ad5/p53 and replication-competent AdF35 produced 
synergistic cytotoxicity through activated p53 pathways although replication of AdF35 itself was 
suppressed. The present study suggests that administration of the dual vectors at an optimized ratio 
can broaden therapeutic options for esophageal carcinoma, which also includes further combination 
with chemotherapy and radiotherapy. 
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Table 1 Infectivity of Ad5 and AdF35 to esophageal carcinoma cells and the p53 status 
 
 
 
 
 
 
 
 
 
 
 
Cells were infected with Ad5/GFP or AdF35/GFP at a 30 MOI and were analyzed for the 
fluorescence with flow cytometry. Averages and the SEs are shown (n=3). 
Cells 
 
P53 status 
 
Mutated codon GFP-positive cells (%) 
 Ad5 AdF35 
TE-1 mutated Codon 272 8.061.17 53.470.10 
TE-2 wild-type  0.790.14 10.150.44 
TE-10 mutated Codon 242 16.150.52 35.330.67 
TE-11 wild-type  22.860.53 42.820.74 
YES-2 mutated Codon 236 5.091.29 51.540.36 
YES-4 wild-type  27.180.16 61.230.07 
YES-5 mutated Codon 280 22.180.32 69.970.89 
YES-6 wild-type  16.590.25 27.630.17 
T.Tn mutated Codon 214 and 258 0.491.00 21.600.15 
HEK293   87.200.52 78.050.70 
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Table 2 Cell cycle distribution after AdF35 infections 
Cells 
 
Treatment 
Time 
(day) 
Cell cycle distribution (%) 
Sub-G1 G0/G1 S G2/M 4N 
T.Tn (-) 3 1.490.08 70.000.17 16.330.16 11.160.08 1.450.06 
 Ad5F35/LacZ 3 1.490.12 65.420.59 19.270.38 12.170.38 2.130.05 
 AdF35/MK 3 5.680.09
* 
46.840.26 13.990.06 12.950.06 20.950.34* 
 AdF35/Sur 3 6.880.10
*
 60.010.05 13.800.26 10.610.22 9.020.16* 
 (-) 4 1.700.07 51.050.25 18.830.15 26.100.14 2.810.16 
 Ad5F35/LacZ 4 2.790.06 66.300.33 14.390.37 15.180.20 1.810.06 
 AdF35/MK 4 15.820.16
*
 37.220.55 13.950.11 11.440.20 22.090.11* 
 AdF35/Sur 4 12.780.41
*
 53.320.50 13.350.29 10.400.17 10.670.07* 
 (-) 5 1.860.15 71.440.17 12.170.12 12.610.17 2.200.09 
 Ad5F35/LacZ 5 1.340.10 72.300.11 14.270.03 10.930.14 1.490.02 
 AdF35/MK 5 34.640.08
*
 30.020.21 15.800.22 7.640.27 12.720.21* 
 AdF35/Sur 5 32.800.27
*
 42.010.06 14.300.17 6.370.15 5.070.05* 
YES-2 (-) 2 2.440.01 46.670.62 23.670.49 24.880.15 3.000.08 
 Ad5F35/LacZ 2 3.010.06 44.780.20 23.420.15 25.700.25 3.750.12 
 AdF35/MK 2 5.280.05
*
 5.890.10 7.110.15 12.130.18 69.950.27* 
 AdF35/Sur 2 5.510.16
*
 11.170.12 9.310.07 14.070.08 60.330.20* 
 (-) 3 3.540.11 51.390.44 21.190.35 21.550.33 2.970.03 
 Ad5F35/LacZ 3 4.600.02 52.040.47 20.810.41 18.890.28 4.360.37 
 AdF35/MK 3 16.920.59
*
 2.200.10 4.450.14 4.130.21 72.400.29* 
 AdF35/Sur 3 28.320.08
*
 2.220.04 2.130.06 3.410.15 64.120.25* 
 (-) 4 2.450.05 57.750.13 22.190.32 14.870.39 3.320.12 
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Cells were infected with AdF35/MK, AdF35/Sur or AdF35/LacZ (1104 vp/cell) or uninfected, and 
then were cultured for the indicated time. Cells cycle profiles were analyzed with flow cytometry. 
Mean percentages with SEs are shown (n=3). 
*
P0. 01; comparing between AdF35/MK- or AdF35/Sur-infected cells and uninfected or 
AdF35/LacZ-infected cells. 
 
 
 
 
 
 
 
 
 
 
 
 Ad5F35/LacZ 4 2.650.14 58.020.75 21.640.25 15.010.58 3.260.13 
 AdF35/MK 4 32.180.23
*
 2.340.02 1.930.05 1.440.10 62.230.28* 
 AdF35/Sur 4 53.861.31
*
 8.421.42 10.350.42 7.58052 20.221.06* 
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Table 3 Combinatory effects of AdF35/MK or AdF35/Sur and Ad5/p53 on cell growth  
Treatment Time (day) Cell numbers (104) 
(-)
 
2 174.34.4 
Ad5/LacZ 2 185.92.4 
Ad5/p53 2 98.34.1 
AdF35/MK
 
2 133.76.1 
AdF35/MK+Ad5/LacZ 2 141.97.1 
AdF35/MK+Ad5/p53 2 28.02.1** 
AdF35/Sur 2 147.71.2 
AdF35/Sur+Ad5/LacZ 2 146.31.8 
AdF35/Sur+Ad5/p53 2 24.33.0** 
(-) 4 747.35.1 
Ad5/LacZ 4 718.210.0 
Ad5/p53 4 57.75.6 
AdF35/MK 4 67.77.0 
AdF35/MK + Ad5/LacZ 4 72.21.5 
AdF35/MK + Ad5/p53 4 3.30.3** 
AdF35/Sur 4 160.03.0 
AdF35/Sur+Ad5/LacZ 4 134.91.2 
AdF35/Sur+Ad5/p53 4 19.32.3** 
(-) 6 1717.71.3 
Ad5/LacZ 6 1838.67.2 
32 
 
YES-2 cells were uninfected or infected with Ad as indicated (AdF35/MK and AdF35/Sur: 1.2 103 
vp/cell; Ad5/p53 and Ad5/LacZ: 6.5 103 vp/cell). Live cell numbers were determined with a trypan 
blue dye exclusion test. Mean percentages with SEs are shown (n=3). 
*
P0. 05, **P0. 01; comparing between AdF35/MK+Ad5/p53-treated or AdF35/Sur+Ad5/p53-
infected cells, and AdF35/MK-treated, AdF35/Sur-infected or Ad5/p53-infected cells. 
 
Ad5/p53 6 1.20.4 
AdF35/MK 6 12.00.6 
AdF35/MK+Ad5/LacZ 6 20.30.3 
AdF35/MK+Ad5/p53 6 00* 
AdF35/Sur
 
6 40.31.3 
AdF35/Sur+Ad5/LacZ 6 87.03.8 
AdF35/Sur+Ad5/p53 6 00* 
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Table 4 Cell cycle distribution after combinatory Ad infections 
YES-2 cells were uninfected or infected with AdF35/MK (1.2103 vp/cell), Ad5/p53, Ad5/LacZ 
(6.5103 vp/cell) or in combination and were cultured for the indicated time. Cell cycle profiles were 
analyzed with flow cytometry. Mean percentages with SEs are shown (n=3). 
 
Treatment 
Time 
(day) 
Cell cycle distribution (%) 
Sub-G1 G0/G1 S G2/M 4N 
(-)  2 
2.080.31 53.330.54 28.071.23 14.391.02 2.520.15 
Ad5/LacZ 2 
1.960.17 44.860.94 31.380.81 18.811.21 3.420.60 
Ad5/p53  2 
7.530.16 58.620.63 16.000.23 17.210.28 1.050.16 
AdF35/MK  2 
4.180.05 28.050.47 21.370.45 22.400.34 24.470.16 
AdF35/MK+Ad5/LacZ  2 
4.120.06 29.280.12 22.030.23 19.970.30 25.040.35 
AdF35/MK+Ad5/p53 2 
28.830.37
*
 31.770.29 18.930.08 16.880.36 4.030.14
*
 
(-)  3 
2.060.16 54.450.19 28.530.13 13.760.21 1.620.26 
Ad5/LacZ 3 
1.220.04 46.560.28 35.300.09 14.820.42 2.440.38 
Ad5/p53  3 
3.090.19 55.830.25 19.620.36 20.750.36 1.130.04 
AdF35/MK  3 
8.970.08 25.020.05 26.060.28 19.280.34 21.300.21 
AdF35/MK+Ad5/LacZ 3 
5.650.52 22.140.52 23.380.48 21.130.36 28.271.06 
AdF35/MK+Ad5/p53 3 
73.710.41
*
 12.410.48 9.140.08 2.940.18 2.160.05
*
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*
P0. 01; comparing between AdF35/MK+Ad5/p53-infected and AdF35/MK- or Ad5/p53-infected 
cells. 
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Figure legends 
Figure 1 
Enhanced cytotoxicity of AdF35. (A) Cell viability of esophageal carcinoma cells that were treated 
with various dose of Ad5/MK, AdF35/MK, Ad5/LacZ or AdF35/LacZ was examined with the WST 
assay. The relative viability was calculated based on the absorbance without any treatments. (B) 
Relative viability of esophageal carcinoma cells treated with various doses of Ad5/Sur, AdF35/Sur, 
Ad5/LacZ or AdF35/LacZ. Standard errors (SE) are shown (n=3). 
 
Figure 2 
Replication-competent Ad-induced activation of apoptosis pathways. T.Tn cells and YES-2 cells 
were uninfected or infected with AdF35/LacZ, AdF35/MK or AdF35/Sur (1104 vp/cell), and 
cultured for the indicated time. (A) Representative flow cytometrical analyses about cell cycle 
changes in YES-2 (day 3) and T.Tn cells (day 4). Expression levels of viral proteins (B), apoptosis- 
(C) and autophagy-linked proteins (D) were analyzed with western blot analyses. GAPDH is used as 
a loading control. 
 
Figure 3 
Anti-tumor effects in vivo produced by AdF35/MK or AdF35/Sur. Nude nice that were 
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subcutaneously injected with YES-2 cells (1x10
6
) were treated on day 7, 10, 13 and 16 with intra-
tumoral injection of AdF35/LacZ, AdF35/MK or AdF35/Sur (2.5x10
8
 pfu/mouse), or with phosphate 
buffered-saline (PBS) as a control. The tumor sizes were measured every 4 days. Means and SE bars 
are shown. 
*
P < 0.01. 
 
Figure 4 
Combinatory cytotoxicity of replication-competent Ad and Ad5/p53. (A) Cells were infected with 
AdF35/MK (at indicate doses), Ad5/p53 (at indicate doses), or AdF35/MK (at the indicated doses) 
plus Ad5/p53 (1.25x10
4
 vp/cell). Relative viability of cells was examined with the WST assay and 
SE bars are shown (n=3). CI values in the combination of AdF35/MK and Ad5/p53 in respective 
fractions affected (Fa) were shown. (B) Cells were infected with AdF35/Sur, Ad5/p53, or AdF35/Sur 
plus Ad5/p53 (1.25x10
4
 vp/cell). CI values in the combination of AdF35/Sur and Ad5/p53 in 
respective Fa points were shown. CI<1, CI=1 and CI>1 indicate synergistic, additive and 
antagonistic actions, respectively.  
 
Figure 5 
(A) Representative flow cytometrical analyses about cell cycle changes. YES-2 cells were uninfected 
or infected with AdF35/MK (1.2103 vp/cell), Ad5/p53, Ad5/LacZ (6.5103 vp/cell) or in 
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combination, and were analyzed on day 2. (B) Anti-tumor effects in vivo produced by AdF35/MK 
and Ad5/p53. Nude mice that were subcutaneously injected with YES-2 cells (1x10
6
) were injected 
with Ad as indicated (1.875x10
8
 pfu/mouse) on day 0, 3, 6 and 9 after the tumors developed to 65 
mm
3
 (n=5). The tumor sizes were measured every 4 days. Means and SE bars are shown. 
*
P < 0.01. 
(C) Influence of Ad/p53 on viral proliferation of replication-competent AdF35. YES-2 cells were 
infected with AdF35/MK or AdF35/Sur and Ad5/p53 or Ad5/LacZ (AdF35/MK and AdF35/Sur: 1.2 
x 10
3 
vp/cell; Ad5/P53, Ad5/LacZ: 6.5 x 10
3
 vp/cell), and the cell lysate was extracted on day 3 or 4. 
The viral titers were assayed with TCID50 method with HEK-293 cells. Means and SE bars are 
shown. 
*
P < 0.05. (D) AdF35/MK-induced phosphorylation of Ad5/p53-derived p53. YES-2 cells 
were infected with AdF35/MK (1.2103 vp/cell) with Ad5/p53 or Ad5/LacZ (6.5103 vp/cell) as a 
control for 2 or 3 days. Eexpression levels of p53 and the phosphorylated p53 at Ser 15 or Ser 46 
residue were analyzed with western blot analyses. -tublin is used as a loading control. 
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